{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:33:04Z","timestamp":1791977584813,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite pharmacotherapy being a significant treatment protocol for attention-deficit\/hyperactivity disorder (ADHD), an increasingly common neurodevelopmental condition among children in Japan, prescribing practices for ADHD medications remain underexplored. This study examined prescribing patterns of medications for ADHD in children and adolescents aged 0\u201317\u2009years in Japan and analyzed drug selection trends on the basis of patients\u2019 backgrounds, including sex, age group, and medical department.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective database study using a large Japanese health insurance claims database, we analyzed prescription patterns from April 2018 to August 2023. We examined the proportion of patients prescribed each of the four ADHD medications, namely, Osmotic controlled-release oral delivery system methylphenidate (OROS-MPH), atomoxetine (ATX), guanfacine (GXR), and lisdexamfetamine (LDX), their combination patterns, and new prescription proportions across different demographic groups and medical departments. The Jonckheere\u2013Terpstra trend test was employed to assess trends in prescription proportions over time. The Mann\u2012Whitney U test was employed to compare time series data on the proportion of monotherapy prescriptions in psychiatric and nonpsychiatric settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 2018 to 2023, OROS-MPH prescriptions significantly decreased from 64.7% to 47.5%, whereas GXR prescriptions significantly increased from 19.3% to 46.4%. GXR was prescribed most frequently for female patients and children aged 6\u201312\u2009years. For new patients, GXR prescriptions began exceeding those of OROS-MPH from late 2019 onward, comprising 41.3% of new prescriptions by 2023. The percentage of patients receiving monotherapy decreased from 82.3% to 79.6%, with OROS-MPH plus GXR being the most common combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In Japan, GXR has become an increasingly preferred medication for ADHD, particularly for female patients and children aged 6\u201312\u2009years, with new prescriptions exceeding those of OROS-MPH since late 2019. This trend may be attributed to GXR not being subject to the same distribution control regulations as central nervous system stimulants and to its distinctive pharmacological mechanisms that differ from those of other ADHD medications. Continuous monitoring of prescription practices is necessary as treatment options continue to evolve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number:<\/jats:title>\n                    <jats:p>Not applicable<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-026-08147-1","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:56:05Z","timestamp":1778763365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prescribing medications for attention-deficit\/hyperactivity disorder in children: a retrospective analysis of a Japanese health insurance claims database"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2758-8573","authenticated-orcid":false,"given":"Ryutaro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Kumazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsei","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Muraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Inada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"8147_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. In: Text revision. 5th. Washington: American Psychiatric Association; 2022.","DOI":"10.1176\/appi.books.9780890425787"},{"issue":"2","key":"8147_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S2215-0366(17)30167-0","volume":"5","author":"K Sayal","year":"2018","unstructured":"Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018;5(2):175\u201386. https:\/\/doi.org\/10.1016\/S2215-0366(17)30167-0.","journal-title":"Lancet Psychiatry"},{"key":"8147_CR3","doi-asserted-by":"publisher","unstructured":"Popit S, Serod K, Locatelli I, Stuhec M. Prevalence of attention-deficit hyperactivity disorder (ADHD): systematic review and meta-analysis. Eur. Psychiatr. 2024, Oct, 9;67(1):e68. https:\/\/doi.org\/10.1192\/j.eurpsy.2024.1786.","DOI":"10.1192\/j.eurpsy.2024.1786"},{"issue":"9","key":"8147_CR4","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.braindev.2013.11.004","volume":"36","author":"K Nomura","year":"2014","unstructured":"Nomura K, Okada K, Noujima Y, Kojima S, Mori Y, Amano M, et al. A clinical study of attention-deficit\/hyperactivity disorder in preschool children\u2014prevalence and differential diagnoses. Brain Dev. 2014;36(9):778\u201385. https:\/\/doi.org\/10.1016\/j.braindev.2013.11.004.","journal-title":"Brain Dev"},{"key":"8147_CR5","doi-asserted-by":"publisher","first-page":"1359872","DOI":"10.3389\/fpsyt.2024.1359872","volume":"15","author":"T Okada","year":"2024","unstructured":"Okada T, Sotodate T, Ogasawara-Shimizu M, Nishigaki N. Psychiatric comorbidities of attention deficit\/hyperactivity disorder in Japan: a nationwide population-based study. Front. Psychiatry. 2024;15:1359872. https:\/\/doi.org\/10.3389\/fpsyt.2024.1359872.","journal-title":"Front. Psychiatry"},{"issue":"2","key":"8147_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3325\/cmj.2015.56.159","volume":"56","author":"M \u0160tuhec","year":"2015","unstructured":"\u0160tuhec M, \u0160vab V, Locatelli I. Prevalence and incidence of attention-deficit\/hyperactivity disorder in Slovenian children and adolescents: a database study from a national perspective. Croat Med J. 2015, Apr;56(2):159\u201365. https:\/\/doi.org\/10.3325\/cmj.2015.56.159.","journal-title":"Croat Med J"},{"issue":"3","key":"8147_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41380-018-0116-3","volume":"24","author":"A Caye","year":"2019","unstructured":"Caye A, Swanson JM, Coghill D, Rohde LA. Treatment strategies for ADHD: an evidence-based guide to select optimal treatment. Mol. Psychiatry. 2019;24(3):390\u2013408. https:\/\/doi.org\/10.1038\/s41380-018-0116-3.","journal-title":"Mol. Psychiatry"},{"key":"8147_CR8","doi-asserted-by":"publisher","unstructured":"Catala-Lopez F, Hutton B, Nunez-Beltran A, Page MJ, Ridao M, Macias Saint-Gerons D, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7):e0180355. https:\/\/doi.org\/10.1371\/journal.pone.0180355.","DOI":"10.1371\/journal.pone.0180355"},{"key":"8147_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jpsychires.2020.01.006","volume":"123","author":"H Boland","year":"2020","unstructured":"Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatric Res. 2020;123:21\u201330. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.01.006.","journal-title":"J Psychiatric Res"},{"key":"8147_CR10","unstructured":"CADDRA - Canadian ADHD Resource Alliance. Canadian ADHD practice guidelines. 2020. https:\/\/adhdlearn.caddra.ca\/wp-content\/uploads\/2022\/08\/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf. 23 Jun 2025. 4.1 ed. Toronto: CADDRA."},{"key":"8147_CR11","unstructured":"NICE - National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. 2018 (updated September 2019). https:\/\/www.nice.org.uk\/guidance\/ng87\/resources\/attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933. 23 Jun 2025."},{"key":"8147_CR12","volume-title":"Guidelines for diagnosis and treatment of attention deficit hyperactivity disease","author":"K Saito","year":"2022","unstructured":"Saito K, Iida J. Guidelines for diagnosis and treatment of attention deficit hyperactivity disease. 5th. Japan: Jiho; 2022.","edition":"5th"},{"issue":"4","key":"8147_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1542\/peds.2019-2528","volume":"144","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF Jr, Allan C, Chan E, Davison D, Earls M, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144(4):144. https:\/\/doi.org\/10.1542\/peds.2019-2528.","journal-title":"Pediatrics"},{"key":"8147_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.eurpsy.2017.01.002","volume":"42","author":"M Stuhec","year":"2017","unstructured":"Stuhec M, Locatelli I. Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: a population-based study. Eur. Psychiatr. 2017, May;42:129\u201333. https:\/\/doi.org\/10.1016\/j.eurpsy.2017.01.002.","journal-title":"Eur. Psychiatr"},{"issue":"2","key":"8147_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/1087054717720719","volume":"24","author":"R Morkem","year":"2020","unstructured":"Morkem R, Patten S, Queenan J, Barber D. Recent trends in the prescribing of ADHD medications in Canadian primary care. J Atten Disord. 2020;24(2):301\u201308. https:\/\/doi.org\/10.1177\/1087054717720719.","journal-title":"J Atten Disord"},{"issue":"10","key":"8147_CR16","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","volume":"5","author":"SR Raman","year":"2018","unstructured":"Raman SR, Man KKC, Bahmanyar S, Berard A, Bilder S, Boukhris T, et al. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases. Lancet Psychiatry. 2018;5(10):824\u201335. https:\/\/doi.org\/10.1016\/S2215-0366(18)30293-1.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"8147_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bcp.13000","volume":"82","author":"C Renoux","year":"2016","unstructured":"Renoux C, Shin JY, Dell\u2019Aniello S, Fergusson E, Suissa S. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in Uk primary care, 1995\u20132015. Brit J Clin Pharma. 2016;82(3):858\u201368. https:\/\/doi.org\/10.1111\/bcp.13000.","journal-title":"Brit J Clin Pharma"},{"issue":"1","key":"8147_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1037\/a0026582","volume":"80","author":"K Bruchm\u00fcller","year":"2012","unstructured":"Bruchm\u00fcller K, Margraf J, Schneider S. Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis. J Consult Clin Psych. 2012;80(1):128\u201338. https:\/\/doi.org\/10.1037\/a0026582.","journal-title":"J Consult Clin Psych"},{"issue":"6","key":"8147_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1542\/peds.2017-3872","volume":"141","author":"SA King","year":"2018","unstructured":"King SA, Casavant MJ, Spiller HA, Hodges NL, Chounthirath T, Smith GA. Pediatric ADHD medication exposures reported to US poison control centers. Pediatrics. 2018;141(6):141. https:\/\/doi.org\/10.1542\/peds.2017-3872.","journal-title":"Pediatrics"},{"issue":"1","key":"8147_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1749-6632.2010.05914.x","volume":"1216","author":"K Wada","year":"2011","unstructured":"Wada K. The history and current state of drug abuse in Japan. Ann New Y Acad Sci. 2011, Jan;1216(1):62\u201372. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05914.x.","journal-title":"Ann New Y Acad Sci"},{"key":"8147_CR21","volume-title":"Guidelines for diagnosis and treatment of attention deficit hyperactivity disease","author":"K Saito","year":"2016","unstructured":"Saito K. Guidelines for diagnosis and treatment of attention deficit hyperactivity disease. 4th. Japan: Jiho; 2016.","edition":"4th"},{"issue":"5","key":"8147_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40263-023-01005-8","volume":"37","author":"NV Radonji\u0107","year":"2023","unstructured":"Radonji\u0107 NV, Bellato A, Khoury NM, Cortese S, Faraone SV. Nonstimulant medications for attention-Deficit\/Hyperactivity disorder (ADHD) in adults: systematic review and meta-analysis. CNS Drugs. 2023, May;37(5):381\u201397. https:\/\/doi.org\/10.1007\/s40263-023-01005-8.","journal-title":"CNS Drugs"},{"issue":"6","key":"8147_CR23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1021\/acschemneuro.7b00173","volume":"8","author":"P Wang","year":"2017","unstructured":"Wang P, Zhang X, Fu T, Li S, Li B, Xue W, et al. Differentiating physicochemical properties between addictive and nonaddictive ADHD drugs revealed by molecular dynamics simulation studies. ACS Chem. Neurosci. 2017;8(6):1416\u201328. https:\/\/doi.org\/10.1021\/acschemneuro.7b00173.","journal-title":"ACS Chem. Neurosci"},{"key":"8147_CR24","doi-asserted-by":"publisher","first-page":"103961","DOI":"10.1016\/j.ajp.2024.103961","volume":"94","author":"K Ishizuka","year":"2024","unstructured":"Ishizuka K. Prescription patterns for attention\u2212deficit hyperactivity disorder (ADHD) medications in Japan: a retrospective claims analysis. Asian J Psychiatr. 2024;94:103961. https:\/\/doi.org\/10.1016\/j.ajp.2024.103961.","journal-title":"Asian J Psychiatr"},{"issue":"6","key":"8147_CR25","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1017\/S2045796018000252","volume":"28","author":"Y Okumura","year":"2019","unstructured":"Okumura Y, Usami M, Okada T, Saito T, Negoro H, Tsujii N, et al. Prevalence, incidence and persistence of ADHD drug use in Japan. Epidemiol Psychiatr Sci. 2019;28(6):692\u201396. https:\/\/doi.org\/10.1017\/S2045796018000252.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"8147_CR26","doi-asserted-by":"publisher","unstructured":"Sasaki Y, Tsujii N, Sasaki S, Sunakawa H, Toguchi Y, Tanase S, et al. Current use of attention-deficit hyperactivity disorder (ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan. PLoS One. 2021;16(6):e0252420. https:\/\/doi.org\/10.1371\/journal.pone.0252420.","DOI":"10.1371\/journal.pone.0252420"},{"issue":"2","key":"8147_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1087054719843179","volume":"24","author":"M Yoshida","year":"2020","unstructured":"Yoshida M, Obara T, Kikuchi S, Satoh M, Morikawa Y, Ooba N, et al. Drug prescriptions for children with ADHD in Japan: a study based on health insurance claims data between 2005 and 2015. J Atten Disord. 2020;24(2):175\u201391. https:\/\/doi.org\/10.1177\/1087054719843179.","journal-title":"J Atten Disord"},{"issue":"2","key":"8147_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.37737\/ace.25006","volume":"7","author":"H Yasunaga","year":"2025","unstructured":"Yasunaga H. DeSC database. Ann Clin Epidemiol. 2025;7(2):46\u201349. https:\/\/doi.org\/10.37737\/ace.25006.","journal-title":"Ann Clin Epidemiol"},{"issue":"1","key":"8147_CR29","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1186\/s12888-021-03409-6","volume":"21","author":"MK Akmatov","year":"2021","unstructured":"Akmatov MK, Holstiege J, Batzing J. Secular trends and regional variations in pharmacotherapy of attention-deficit\/hyperactivity disorder (ADHD) among children and adolescents in Germany. BMC Psychiatry. 2021;21(1):405. https:\/\/doi.org\/10.1186\/s12888-021-03409-6.","journal-title":"BMC Psychiatry"},{"key":"8147_CR30","unstructured":"Instituto Aragon\u00e9s de Ciencias de la Salud. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica sobre las Intervenciones Terap\u00e9uticas en el Trastorno por D\u00e9ficit de Atenci\u00f3n con Hiperactividad (TDAH). 2017. https:\/\/portal.guiasalud.es\/wp-content\/uploads\/2018\/12\/GPC_574_TDAH_IACS_compl.pdf. 1 Dec 2025. Zaragoza: IACS."},{"issue":"3","key":"8147_CR31","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/10870547221136226","volume":"27","author":"JA Ramos-Quiroga","year":"2023","unstructured":"Ramos-Quiroga JA, Richarte V, Soto I, Targhetta M, Ward J, Perulero N. The prevalence and treatment of ADHD in Spain: a retrospective cohort analysis. J Atten Disord. 2023;27(3):273\u201382. https:\/\/doi.org\/10.1177\/10870547221136226.","journal-title":"J Atten Disord"},{"issue":"1","key":"8147_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/npr2.12381","volume":"44","author":"K Kawabe","year":"2024","unstructured":"Kawabe K, Horiuchi F, Matsumoto Y, Inoue S, Okazawa M, Hosokawa R, et al. Practical clinical guidelines and pharmacological treatment for attention-deficit hyperactivity disorder in Asia. Neuropsychopharm Rep. 2024, Mar;44(1):29\u201333. https:\/\/doi.org\/10.1002\/npr2.12381.","journal-title":"Neuropsychopharm Rep"},{"issue":"3","key":"8147_CR33","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1089\/cap.2014.0071","volume":"25","author":"M \u0160tuhec","year":"2015","unstructured":"\u0160tuhec M, Locatelli I, \u0160vab V. Trends in attention-deficit\/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective. J Child Adolesc Psychopharmacol. 2015, Apr;25(3):254\u201359. https:\/\/doi.org\/10.1089\/cap.2014.0071.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"13","key":"8147_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.15585\/mmwr.mm7213a1","volume":"72","author":"ML Danielson","year":"2023","unstructured":"Danielson ML, Bohm MK, Newsome K, Claussen AH, Kaminski JW, Grosse SD, et al. Trends in stimulant prescription fills among commercially insured children and adults \u2014 United States, 2016\u20132021. MMWR Morb. Mortal. Wkly. Rep. 2023;72(13):327\u201332. https:\/\/doi.org\/10.15585\/mmwr.mm7213a1.","journal-title":"MMWR Morb. Mortal. Wkly. Rep"},{"issue":"1","key":"8147_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12888-024-05505-9","volume":"24","author":"S Gimbach","year":"2024","unstructured":"Gimbach S, Vogel D, Fried R, Faraone SV, Banaschewski T, Buitelaar J, et al. ADHD medicine consumption in Europe after COVID-19: catch-up or trend change? BMC Psychiatry. 2024;24(1):112. https:\/\/doi.org\/10.1186\/s12888-024-05505-9.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"8147_CR36","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1586\/14737175.2014.908707","volume":"14","author":"WD Graf","year":"2014","unstructured":"Graf WD, Miller G, Nagel SK. Addressing the problem of ADHD medication as neuroenhancements. Expert Rev Neurotherapeutics. 2014;14(5):569\u201381. https:\/\/doi.org\/10.1586\/14737175.2014.908707.","journal-title":"Expert Rev Neurotherapeutics"},{"issue":"12","key":"8147_CR37","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.euroneuro.2014.09.014","volume":"24","author":"A Hervas","year":"2014","unstructured":"Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol. 2014;24(12):1861\u201372. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.09.014.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"8","key":"8147_CR38","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00787-017-0962-6","volume":"26","author":"A Joseph","year":"2017","unstructured":"Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, et al. Comparative efficacy and safety of attention-deficit\/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26(8):875\u201397. https:\/\/doi.org\/10.1007\/s00787-017-0962-6.","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"11","key":"8147_CR39","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-013-0102-x","volume":"27","author":"V Sikirica","year":"2013","unstructured":"Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, et al. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs. 2013;27(11):943\u201353. https:\/\/doi.org\/10.1007\/s40263-013-0102-x.","journal-title":"CNS Drugs"},{"key":"8147_CR40","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2147\/NDT.S94158","volume":"12","author":"K Murkett","year":"2016","unstructured":"Murkett K, Sikirica V, Hervas A, Newcorn JH, Harpin V, Robertson B, et al. Guanfacine extended release for children and adolescents with attention-deficit\/hyperactivity disorder: efficacy following prior methylphenidate treatment. NDT. 2016;12:1085\u2013101. https:\/\/doi.org\/10.2147\/NDT.S94158.","journal-title":"NDT"},{"issue":"1","key":"8147_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00127-009-0041-5","volume":"45","author":"AGM Bulloch","year":"2010","unstructured":"Bulloch AGM, Patten SB. Non-adherence with psychotropic medications in the general population. Soc Psychiat Epidemiol. 2010;45(1):47\u201356. https:\/\/doi.org\/10.1007\/s00127-009-0041-5.","journal-title":"Soc Psychiat Epidemiol"},{"key":"8147_CR42","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2147\/PPA.S44646","volume":"7","author":"A Sadosky","year":"2013","unstructured":"Sadosky A, Srivastava K, Arora A, Kataria A, Sadosky C, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. PPA. 2013;7:419\u201334. https:\/\/doi.org\/10.2147\/PPA.S44646.","journal-title":"PPA"},{"issue":"3","key":"8147_CR43","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/1087054706292165","volume":"10","author":"SA Safren","year":"2007","unstructured":"Safren SA, Duran P, Yovel I, Perlman CA, Sprich S. Medication adherence in psychopharmacologically treated adults with ADHD. J Atten Disord. 2007;10(3):257\u201360. https:\/\/doi.org\/10.1177\/1087054706292165.","journal-title":"J Atten Disord"},{"issue":"3","key":"8147_CR44","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1177\/108705470200500302","volume":"5","author":"J Gershon","year":"2002","unstructured":"Gershon J, Gershon J. A meta-analytic review of gender differences in ADHD. J Atten Disord. 2002;5(3):143\u201354. https:\/\/doi.org\/10.1177\/108705470200500302.","journal-title":"J Atten Disord"},{"issue":"4","key":"8147_CR45","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00787-018-1211-3","volume":"28","author":"FD Mowlem","year":"2019","unstructured":"Mowlem FD, Rosenqvist MA, Martin J, Lichtenstein P, Asherson P, Larsson H. Sex differences in predicting ADHD clinical diagnosis and pharmacological treatment. Eur Child Adolesc Psychiatry. 2019;28(4):481\u201389. https:\/\/doi.org\/10.1007\/s00787-018-1211-3.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"8147_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11537790-000000000-00000","volume":"24","author":"DF Connor","year":"2010","unstructured":"Connor DF, Findling RL, Kollins SH, Sallee F, L\u00f3pez FA, Lyne A, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6\u201312 years with attention-deficit hyperactivity disorder and oppositional symptoms. CNS Drugs. 2010;24:1\u201368. https:\/\/doi.org\/10.2165\/11537790-000000000-00000.","journal-title":"CNS Drugs"},{"issue":"7","key":"8147_CR47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1176\/appi.ps.201600130","volume":"68","author":"A Patel","year":"2017","unstructured":"Patel A, Medhekar R, Ochoa-Perez M, Aparasu RR, Chan W, Sherer JT, et al. Care provision and prescribing practices of physicians treating children and adolescents with ADHD. Psychiatr Serv. 2017;68(7):681\u201388. https:\/\/doi.org\/10.1176\/appi.ps.201600130.","journal-title":"Psychiatr Serv"},{"key":"8147_CR48","unstructured":"Ministry of Health. Labour and welfare. Survey of physicians, dentists and pharmacists 2022. Last updated Dec 2024. https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/ishi\/22\/dl\/R04_kekka-1.pdf. 8 Dec 2025."},{"issue":"1","key":"8147_CR49","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12888-022-04290-7","volume":"22","author":"P Asherson","year":"2022","unstructured":"Asherson P, Leaver L, Adamou M, Arif M, Askey G, Butler M, et al. Mainstreaming adult ADHD into primary care in the UK: guidance, practice, and best practice recommendations. BMC Psychiatry. 2022, Oct, 11;22(1):640. https:\/\/doi.org\/10.1186\/s12888-022-04290-7.","journal-title":"BMC Psychiatry"},{"key":"8147_CR50","doi-asserted-by":"publisher","unstructured":"Yamaguchi S, Okada A, Sunaga S, Ikeda Kurakawa K, Yamauchi T, Nangaku M, et al. Impact of COVID-19 pandemic on healthcare service use for non-COVID-19 patients in Japan: retrospective cohort study. BMJ Open. 2022;12(4):e060390. https:\/\/doi.org\/10.1136\/bmjopen-2021-060390.","DOI":"10.1136\/bmjopen-2021-060390"},{"issue":"3","key":"8147_CR51","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/cap.2020.0162","volume":"31","author":"M Baker","year":"2021","unstructured":"Baker M, Huefner JC, Bellonci C, Hilt R, Carlson GA. Polypharmacy in the management of attention-deficit\/hyperactivity disorder in children and adolescents: a review and update. J Child Adolesc Psychopharmacol. 2021;31(3):148\u201363. https:\/\/doi.org\/10.1089\/cap.2020.0162.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"8147_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1753-2000-1-10","volume":"1","author":"GA Carlson","year":"2007","unstructured":"Carlson GA, Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L, et al. A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2007;1(1):10. https:\/\/doi.org\/10.1186\/1753-2000-1-10.","journal-title":"Child Adolesc Psychiatry Ment Health"},{"issue":"8","key":"8147_CR53","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.jaac.2016.05.015","volume":"55","author":"JT McCracken","year":"2016","unstructured":"McCracken JT, McGough JJ, Loo SK, Levitt J, Del\u2019homme M, Cowen J, et al. Combined stimulant and guanfacine administration in attention-deficit\/hyperactivity disorder: a controlled, comparative study. J Am Acad Child Psy. 2016;55(8):657\u201366.e1. https:\/\/doi.org\/10.1016\/j.jaac.2016.05.015.","journal-title":"J Am Acad Child Psy"},{"issue":"2","key":"8147_CR54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/1087054717751197","volume":"24","author":"van Stralen Jpm","year":"2020","unstructured":"van Stralen Jpm, van Stralen JPM. A controlled trial of extended-release guanfacine and psychostimulants on executive function and ADHD. J Atten Disord. 2020;24(2):318\u201325. https:\/\/doi.org\/10.1177\/1087054717751197.","journal-title":"J Atten Disord"},{"issue":"3","key":"8147_CR55","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/npr2.12122","volume":"40","author":"K Ichihashi","year":"2020","unstructured":"Ichihashi K, Hori H, Hasegawa N, Yasuda Y, Yamamoto T, Tsuboi T, et al. Prescription patterns in patients with schizophrenia in Japan: first-quality indicator data from the survey of \u201ceffectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)\u201d project. Neuropsychopharm Rep. 2020;40(3):281\u201386. https:\/\/doi.org\/10.1002\/npr2.12122.","journal-title":"Neuropsychopharm Rep"},{"issue":"12","key":"8147_CR56","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/pcn.13143","volume":"74","author":"H Iida","year":"2020","unstructured":"Iida H, Iga J, Hasegawa N, Yasuda Y, Yamamoto T, Miura K, et al. Unmet needs of patients with major depressive disorder \u2013 findings from the \u2018E ffectiveness of G uidelines for D issemination and E ducation in P sychiatric T reatment (EGUIDE)\u2019 project: a nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci. 2020;74(12):667\u201369. https:\/\/doi.org\/10.1111\/pcn.13143.","journal-title":"Psychiatry Clin Neurosci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-08147-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08147-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-08147-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:53:18Z","timestamp":1783569198000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-08147-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8147"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-08147-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7008746\/v1","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Review Committee of Meiji Pharmaceutical University approved this study on June 27, 2024 (registration number: 202408). As the data used in this study were unlinked and anonymous, informed consent was not needed. All methods were carried out in accordance with relevant guidelines and regulations, including the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ken Inada has received personal fees from the following companies over the past three years: EA Pharma Co., Ltd., Viatris Pharmaceuticals Japan Inc., Eisai Co., Ltd., MSD K.K., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Kowa Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., Daiichi Sankyo Co., Limited., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation., Nipro Corporation, Nippon Chemiphar Co., Ltd., Eli Lilly Japan K.K., Boehringer Ingelheim Japan, Inc., Nexera Pharma K.K., Novartis Pharma K.K., Nobelpharma Co., Ltd., Pfizer Japan Inc., Meiji Seika Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Lundbeck Japan K.K., and Yoshitomi Pharmaceutical Industries, Ltd. Manabu Akazawa has received speaker honoraria and consultancy fees from Astellas Pharma Inc., Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., Merck & Co., Ltd. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}